Martyrs & Models: Early Returns from the AMNOG Era
During the past few months, IQWiG has made several decisions public for recently reviewed drugs. For the first time, a body of evidence exists which can shed some light upon how restrictive and how timely access will be under the new AMNOG legislation regime in Germany. Some brands have been particularly fortunate, however these positive outcomes have more to do with compliance with G-BA’s requests than it has to do with whether the product is actually providing clinical benefit or not. To better understand how the future access environment in Germany will take shape, each of the brands reviewed to date has been assessed for key learnings as brand managers plan for the new Germany. A full assessment against the outcomes in England, Scotland, and France also reveals how demanding the G-BA and IQWiG are shaping up to be.
By Cyrus Chowdhury, Practice Leader, Global Market Access, Insight Strategy Advisors.
Have Your Say
Rate this feature and give us your feedback in the comments section below
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.